(MedPage Today) — SAN FRANCISCO — The adjuvant combination of pembrolizumab (Keytruda) and belzutifan (Welireg) significantly improved disease-free survival (DFS) in patients with clear cell renal cell carcinoma (ccRCC) after nephrectomy versus…
Source link : https://www.medpagetoday.com/meetingcoverage/mgucs/120099
Author :
Publish date : 2026-02-28 22:17:00
Copyright for syndicated content belongs to the linked Source.
